Abstract
This preliminary study investigated genomic biomarkers for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), related to three antiepileptic drugs, zonisamide, phenobarbital and phenytoin. Patients & methods: HLA class I and HLA-DRB1 loci were genotyped for Japanese patients with zonisamide-, phenobarbital- or phenytoin-induced SJS/TEN (n = 12, 8 and 9, respectively) and for healthy Japanese volunteers (n = 2878). Results: Carrier frequencies of HLA-A*02:07 in patients with zonisamide-induced SJS/TEN and in the general Japanese population were 41.7 and 6.81%, respectively. Carrier frequencies of HLA-B*51:01 in patients with phenobarbital- and phenytoin-induced SJS/TEN and in controls were 75.0, 55.6 and 15.2%, respectively. HLA-A*02:07 and HLA-B*51:01, in a dominant model, were significantly associated with zonisamide- and phenobarbital-induced SJS/TEN, respectively (Pc = 0.0176 and 0.0042, respectively). Conclusion: Our data suggest that HLA-A*02:07 and HLA-B*51:01 are potential biomarkers for zonisamide- and phenobarbital-induced SJS/TEN, respectively, in Japanese individuals.
| Original language | English |
|---|---|
| Pages (from-to) | 1821-1831 |
| Number of pages | 11 |
| Journal | Pharmacogenomics |
| Volume | 14 |
| Issue number | 15 |
| DOIs | |
| Publication status | Published - 01-11-2013 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Molecular Medicine
- Genetics
- Pharmacology
Cite this
}
Specific HLA types are associated with antiepileptic drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese subjects. / Kaniwa, Nahoko; Sugiyama, Emiko; Saito, Yoshiro; Kurose, Kouichi; Maekawa, Keiko; Hasegawa, Ryuichi; Furuya, Hirokazu; Ikeda, Hiroko; Takahashi, Yukitoshi; Muramatsu, Masaaki; Tohkin, Masahiro; Ozeki, Takeshi; Mushiroda, Taisei; Kubo, Michiaki; Kamatani, Naoyuki; Abe, Masamichi; Yagami, Akiko; Ueta, Mayumi; Sotozono, Chie; Kinoshita, Shigeru; Ikezawa, Zenro; Matsunaga, Kayoko; Aihara, Michiko.
In: Pharmacogenomics, Vol. 14, No. 15, 01.11.2013, p. 1821-1831.Research output: Contribution to journal › Article
TY - JOUR
T1 - Specific HLA types are associated with antiepileptic drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese subjects
AU - Kaniwa, Nahoko
AU - Sugiyama, Emiko
AU - Saito, Yoshiro
AU - Kurose, Kouichi
AU - Maekawa, Keiko
AU - Hasegawa, Ryuichi
AU - Furuya, Hirokazu
AU - Ikeda, Hiroko
AU - Takahashi, Yukitoshi
AU - Muramatsu, Masaaki
AU - Tohkin, Masahiro
AU - Ozeki, Takeshi
AU - Mushiroda, Taisei
AU - Kubo, Michiaki
AU - Kamatani, Naoyuki
AU - Abe, Masamichi
AU - Yagami, Akiko
AU - Ueta, Mayumi
AU - Sotozono, Chie
AU - Kinoshita, Shigeru
AU - Ikezawa, Zenro
AU - Matsunaga, Kayoko
AU - Aihara, Michiko
PY - 2013/11/1
Y1 - 2013/11/1
N2 - This preliminary study investigated genomic biomarkers for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), related to three antiepileptic drugs, zonisamide, phenobarbital and phenytoin. Patients & methods: HLA class I and HLA-DRB1 loci were genotyped for Japanese patients with zonisamide-, phenobarbital- or phenytoin-induced SJS/TEN (n = 12, 8 and 9, respectively) and for healthy Japanese volunteers (n = 2878). Results: Carrier frequencies of HLA-A*02:07 in patients with zonisamide-induced SJS/TEN and in the general Japanese population were 41.7 and 6.81%, respectively. Carrier frequencies of HLA-B*51:01 in patients with phenobarbital- and phenytoin-induced SJS/TEN and in controls were 75.0, 55.6 and 15.2%, respectively. HLA-A*02:07 and HLA-B*51:01, in a dominant model, were significantly associated with zonisamide- and phenobarbital-induced SJS/TEN, respectively (Pc = 0.0176 and 0.0042, respectively). Conclusion: Our data suggest that HLA-A*02:07 and HLA-B*51:01 are potential biomarkers for zonisamide- and phenobarbital-induced SJS/TEN, respectively, in Japanese individuals.
AB - This preliminary study investigated genomic biomarkers for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), related to three antiepileptic drugs, zonisamide, phenobarbital and phenytoin. Patients & methods: HLA class I and HLA-DRB1 loci were genotyped for Japanese patients with zonisamide-, phenobarbital- or phenytoin-induced SJS/TEN (n = 12, 8 and 9, respectively) and for healthy Japanese volunteers (n = 2878). Results: Carrier frequencies of HLA-A*02:07 in patients with zonisamide-induced SJS/TEN and in the general Japanese population were 41.7 and 6.81%, respectively. Carrier frequencies of HLA-B*51:01 in patients with phenobarbital- and phenytoin-induced SJS/TEN and in controls were 75.0, 55.6 and 15.2%, respectively. HLA-A*02:07 and HLA-B*51:01, in a dominant model, were significantly associated with zonisamide- and phenobarbital-induced SJS/TEN, respectively (Pc = 0.0176 and 0.0042, respectively). Conclusion: Our data suggest that HLA-A*02:07 and HLA-B*51:01 are potential biomarkers for zonisamide- and phenobarbital-induced SJS/TEN, respectively, in Japanese individuals.
UR - http://www.scopus.com/inward/record.url?scp=84893344987&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84893344987&partnerID=8YFLogxK
U2 - 10.2217/PGS.13.180
DO - 10.2217/PGS.13.180
M3 - Article
C2 - 24236482
AN - SCOPUS:84893344987
VL - 14
SP - 1821
EP - 1831
JO - Pharmacogenomics
JF - Pharmacogenomics
SN - 1462-2416
IS - 15
ER -